Company Overview and News

154
Micron Technology: The Current Stock Price Means No Growth Forever

2018-06-04 seekingalpha
In my previous article, I have written about why Micron Technology (MU) is worth around $90 per share, with my conservative assumptions. I also pointed out after going up a lot, it might experience a short-term pullback. And it did. Last Thursday, its shares lost nearly 8% in a single day, erasing most of the month's gain.
SSNNF SSNLF HXSCF MS.PRE MS.PRF MS.PRG MS.PRA MS.PRI MU MS.PRK MS INTC HXSCL

204
Samsung Electronics: 5G And AI Create A New Cycle

2018-05-28 seekingalpha
We maintain BUY and our six-month-forward target price of KRW66,000 (the average of 10x 2018F EPS and 1.7x 2018F BPS, after the stock split) on Samsung Electronics (OTC:SSNLF)(OTC:SSNNF). We now believe Samsung will report KRW61.2tn in revenue and KRW15.7tn in operating profit for 2Q18, mostly unchanged from our previous estimates. We slightly raise our 2Q operating profit forecast is because we expect DRAM prices to increase more sharply than we previously thought.
SSNNF SSNLF HXSCF AAPL BC94 SMSN INTC HXSCL SMSD

144
Micron Technology Is Worth More Than $90 Per Share, 50% Upside

2018-05-28 seekingalpha
Industry consolidation improves return on investments for overall memory and storage industry to as high as 30%.
SSNNF SSNLF HXSCF MU INTC HXSCL

35
Micron's DRAM Money Machine

2018-05-18 seekingalpha
Micron (MU) has an attractive PE ratio which a lot of investors are interested in. At 6.55, it’s quite low compared to others in the industry. However, in my article I would like to focus on something I think is really important for a manufacturing company with a high CAPEX like Micron and that is free cash flow per share and then where that cash is mostly coming from.
SSNNF SSNLF HXSCF INTC HXSCL

11
Lenovo: Risk/Reward Still Not Attractive

2018-04-30 seekingalpha
With the shares trading at a multi-year low and sentiment apparently at rock bottom, Lenovo is an attractive target for bargain hunters.
SSNNF LNVGF SSNLF LNVGY INPRF 0992

11
Micron Is Sitting In The Catbird Seat

2018-03-22 seekingalpha
The company's top line growth has been gaudy, driven by rising demand and pricing for DRAM.
SSNNF SSNLF

317
Why Semiconductors Are Hot And 'Retail' Tech Is Not - Yet

2018-03-12 seekingalpha
Have you noticed a lull in consumer technology in the last year and how 'innovation' to the end user has stalled?
FB SSNNF SSNLF AAPL WDC MSFT NVDA INTC

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

CUSIP: Y74718118